company background image
CALA logo

Calithera Biosciences OTCPK:CALA Stock Report

Last Price

US$0.02

Market Cap

US$122.1k

7D

0%

1Y

-60.0%

Updated

25 Mar, 2024

Data

Company Financials

Calithera Biosciences, Inc.

OTCPK:CALA Stock Report

Market Cap: US$122.1k

CALA Stock Overview

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023.

CALA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Calithera Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Calithera Biosciences
Historical stock prices
Current Share PriceUS$0.02
52 Week HighUS$0.50
52 Week LowUS$0.01
Beta-0.22
1 Month Change-20.16%
3 Month Change-33.33%
1 Year Change-60.00%
3 Year Change-99.96%
5 Year Change-99.99%
Change since IPO-99.99%

Recent News & Updates

Recent updates

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Oct 03

Calithera rises 8% after HC Wainwright upgrades rating to buy

Aug 29

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

The Upcoming Calithera Cystic Fibrosis Data Could Be Significant

Aug 03

Calithera Biosciences Investor Presentation - Slideshow

May 08

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

May 02
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Mar 10
What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jan 17
Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Calithera sinks as telaglenastat fails in kidney cancer study; lowers headcount

Jan 04

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Dec 13
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Calithera Biosciences Poised For Long-Term Success

Nov 25

Calithera Biosciences (CALA) Investor Presentation - Slideshow

Nov 06

Shareholder Returns

CALAUS BiotechsUS Market
7D0%0.2%1.3%
1Y-60.0%10.2%29.8%

Return vs Industry: CALA underperformed the US Biotechs industry which returned 9.8% over the past year.

Return vs Market: CALA underperformed the US Market which returned 30.4% over the past year.

Price Volatility

Is CALA's price volatile compared to industry and market?
CALA volatility
CALA Average Weekly Movement22.3%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: CALA's share price has been volatile over the past 3 months.

Volatility Over Time: CALA's weekly volatility has decreased from 152% to 22% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20109Susan Molineauxhttps://www.calithera.com

Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Calithera Biosciences, Inc. Fundamentals Summary

How do Calithera Biosciences's earnings and revenue compare to its market cap?
CALA fundamental statistics
Market capUS$122.06k
Earnings (TTM)-US$21.29m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CALA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$28.53m
Gross Profit-US$28.53m
Other Expenses-US$7.24m
Earnings-US$21.29m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-4.37
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CALA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.